Clinical Trials & Research
Oncology Nurse Navigators
High-Risk Cancer Genetics
See All Your Doctors in One Visit
Events & Support Groups
Fitness & Wellness
Family Cancer Resource Center
Home > Testing & Treatment > Clinical Trials & Research
Treatment options, finding physicians or seeking second opinions? Let us help you find the answers. Contact us.
Clinical trials are research studies that have been carefully designed to answer questions about new ways to prevent cancer, treat cancer, and manage side effects of treatment.
The Hall-Perrine Cancer Center participates in national clinical trials through the National Cancer Institute (NCI) and national and international studies through the pharmaceutical industry. These types of clinical trials are leading to major breakthroughs in cancer treatment in our own community.
Through the Iowa-Wide Oncology Research Coalition (I-WORC), Oncology Associates at Mercy Medical Center actively participates in more than 45 clinical trials at any given time. This allows a great number of patients access to trials based on the cancer and stage of cancer.
For more information about clinical trials, contact:
Jeanne Noble, at (319) 363-2690 ext. 1 or email@example.com
Laurie Burke, at (319) 363-2690 ext. 2 or Lburke@mercycare.org
ALTernate Approaches for Clinical Stage II and III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study (NCT01953588) Arm 1 open
Rand Ph III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Br Ca Pts (CT1-3N1) who have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Ph III Rand, Placebo-Controlled Trial Evaluating Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Pts w/ High-Risk, Hormone Receptor-Positive & HER2/NEU Negative Breast Cancer
Rand Ph III Trial of Adjuvant Therapy Comparing Doxorubicin + Cyclophosphamide Followed by Weekly Paclitaxel w/ or w/o Carboplatin for Node-Positive or High-Risk Node-Negative Triple Negative Invasive Breast Cancer
A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer
Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A Companion to Alliance Study A011502
A171601: A Phase II Trial Assessing the Tolerability of Palbociclib in Combination with Letrozole or Fulvestrant in Patients Aged 70 and Older with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer
S0820: Double-Blind Placebo-Controlled Trial of Eflornithine & Sulindac to Prevent Recurrence of High Risk Adenomas & Second Primary Colorectal Cancers in Pts w/ Stage 0-III Colon or Rectal Ca, Ph III- Preventing Adenomas of the Colon w/ Eflornithine & Sulindac (PACES)
A021502: Randomized Trial of Standard Chemotherapy Alone orCombined with Atezolizumab as Adjuvant Therapy for Patients with Stage IIIColon Cancer and Deficient DNA Mismatch Repair
Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial
A Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy
Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients with Head and Neck Cancer
The National Myelodysplastic Syndromes (MDS) Study
Adjuvant Lung Cancer Enrichment Marker Identification & Sequencing Trial (ALCHEMIST) **Screening trial for A081105, E4512, & EA5142**
Rand, Double-Blind, Placebo-Controlled Study of Erlotinib or Placebo in Pts w/ Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant NSCLC **Must be enrolled on screening trial A151216**
Ph III Double-Blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib Vs. Placebo for Pts w/ Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein **Must be enrolled on screening trial A151216**
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers **Must be enrolled on screening trial A151216**
A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
WF-10217: Work Ability in Young Adult Survivors (WAYS)
EAQ162CD: Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
A221602: OlanzapineWith or Without Fosaprepitant for the Prevention of Chemotherapy Induced Nauseaand Vomiting (CINV)in Patients Receiving Highly Emetogenic Chemotherapy (HEC):A Phase III Randomized, Double Blind, Placebo-Controlled Trial
Please note: Participation in clinical trials require that participants meet very specific eligibility criteria. Please check with your physician to see if you may be eligible. This website is periodically updated to list studies currently available. Please speak with your doctor to inquire if a particular clinical trial is currently enrolling patients.
Clinical Trials Matching Service is a free, confidential program that helps patients, their families and healthcare professionals find cancer clinical trials most appropriate to a specific patient, taking their medical and personal history in consideration. For more information, call 1-800-303-5691 or visit http://cancer.org/clinicaltrials.
The National Cancer Institute (NCI) offers a clinical trials search feature along with patient education on clinical trials. For more information, go to http://www.cancer.gov/clinicaltrials.